Cyprus has Europe’s highest rate of bloodstream infections from Klebsiella bacteria resistant to powerful carbapenem antibiotics, almost six times the European average, EU health agency data released on Wednesday showed.
According to the European Centre for Disease Prevention and Control (ECDC), Cyprus recorded an estimated 21.29 such infections per 100,000 people in 2025, up from 5.51 in 2021 and 19.81 in 2024. That was the highest rate among the EU and European Economic Area countries in the data, compared with a European average of about 3.7.
Carbapenems are used to treat serious infections, and resistance to them limits the treatment options available. Klebsiella can cause pneumonia, urinary tract infections and bloodstream infections, which can sometimes develop into life-threatening sepsis. Resistant strains are a major challenge for hospitals because they more often affect patients who are already in poor health. Several of the bacteria in the data can cause serious infections in vulnerable patients and spread within healthcare settings.
Other resistant bacteria
Infections from Klebsiella resistant to third-generation cephalosporins, another class of antibiotics, reached 30.28 per 100,000 in Cyprus in 2025, compared with about 9.2 across Europe, up from 11.46 in 2021.
Bloodstream infections from E. coli resistant to the same antibiotics stood at 23.30 in 2025, against a European figure of about 12, up from 9.37 in 2021 and 19.56 in 2024. E. coli normally lives in the gut, but some strains mainly cause urinary tract infections and, in more serious cases, kidney and bloodstream infections.
The rate for methicillin-resistant Staphylococcus aureus (MRSA) was 12.07 in 2025, compared with a European average of about 4.5, although it fell from 13.63 in 2024.
Carbapenem-resistant Acinetobacter showed a marked improvement, falling to 7.57 in 2025 from 29.61 in 2021, though it remains above the European average. The bacterium mainly infects hospital patients, particularly in intensive care units, and can cause pneumonia, wound infections and serious bloodstream infections.
Europe off target
Across the EU, bloodstream infections from carbapenem-resistant Klebsiella rose by 72 per cent between 2019 and 2025, against a 2030 target of a 5 per cent reduction, according to the ECDC. Infections from E. coli resistant to third-generation cephalosporins rose by 16.4 per cent, against a target of a 10 per cent cut.
MRSA bloodstream infections have fallen by 19 per cent since 2019, but the ECDC warned that the increase recorded over the past two years could put that progress at risk.
Marking European Antibiotic Awareness Day, the agency said the spread of resistant bacteria was gradually narrowing treatment options and required coordinated action by health systems. Tackling resistance was not only about using fewer antibiotics, it said, but also required strong surveillance, effective prevention of transmission and early identification of resistant organisms.
The ECDC also stressed the need for effective infection prevention and control, adequate staffing, the ability to isolate patients, more laboratory testing and prudent use of antibiotics.
Expert warning
Constantinos Tsioutis, scientific coordinator of the European Committee on Infection Control (EUCIC) and dean of the medical school at European University Cyprus, said Cyprus consistently ranked among the EU member states with the highest antibiotic consumption, the highest levels of antimicrobial resistance and the highest rates of hospital-acquired infections.
He said antimicrobial resistance was among the ten biggest threats to public health worldwide. Without effective antimicrobial drugs, he warned, even basic achievements of modern medicine, such as transplants, chemotherapy and surgery, could become unsafe.
Tsioutis expressed particular concern about the overuse of broad-spectrum antibiotics in the community and in hospitals, and about their use for viral infections such as colds and flu, against which they have no effect. He urged caution over giving antibiotics to children unnecessarily, and noted that the use of antimicrobials in livestock farming and agriculture also affects the environment.
Despite measures in Cyprus to strengthen surveillance and the work of antibiotic stewardship and infection control teams in hospitals, tackling the problem “requires intensive, coordinated and continuous efforts”, he said.




